KEYNOTE-091 data presentation
KEYTRUDA® (pembrolizumab) as monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma (NSCLC) who are at high risk of recurrence following complete resection and platinum-based chemotherapy

Prescribing Information [External link]

Download our KEYNOTE-091 slide deck that discusses the clinical data for KEYTRUDA as adjuvant therapy for completely resected Stage IB-IIIA* NSCLC.
*AJCC 7th Edition

Please refer to the KEYTRUDA Summary of Product Characteristics and Risk Minimisation Materials before prescribing KEYTRUDA. Risk Minimisation Materials are available online, from your MSD representative or from MSD Medical Information (Email: medicalinformationuk@msd.com, Phone: 0208 154 8000).

Find out more information about KEYTRUDA in early stage NSCLC

Supporting documentation

Prescribing Information [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.